Vanderbilt Clinical Trials

• ≥18 years of age at the time of consent. - ECOG performance status of 0 or 1. - Documented diagnosis of MM per IMWG diagnostic criteria. - Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. - Have documented evidence of progressive disease per IMWG criteria. - Participant must have measurable disease at screening. - Participant must have adequate bone marrow and organ function (hematological, hepatic and renal) demonstrated at screening.

: - Participant has a history of significant toxicity during prior CAR T-cell therapy and T-cell engaging therapy. - Participant has a history of a prior non-hematologic malignancy, unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years. Some exceptions may apply. - Participant has significant cardiac, neurological, or psychiatric conditions. - Any other significant medical conditions such as: - Serious active or uncontrolled infection - Active autoimmune disease or a history of autoimmune disease within 2 years - Active plasma cell leukemia at the time of screening - Clinical evidence of dementia or altered mental status, or stroke, intracranial haemorrhage, or seizure within 6 months before signing informed consent form (ICF). - Known active or prior history of central nervous system involvement or exhibits clinical signs of meningeal involvement of MM. Other protocol-defined Inclusion/Exclusion criteria apply.